Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Adverse effects of acquisitions in the pharmaceutical industry

Publicly funded research leads to the development of many new drugs, but the profits are largely reaped by big pharmaceutical companies through exclusive licensing deals, mergers and acquisitions, which can reduce competition and patients’ access to medicines.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Ownership changes for approved CAR-T therapies.


  1. Galkina Cleary, E. et al. Proc. Natl Acad. Sci. USA 115, 2329–2334 (2018).

    Article  Google Scholar 

  2. Cunningham, C. et al. J. Polit. Econ. 129, 649–702 (2021).

    Article  Google Scholar 

  3. IQVIA MIDAS Database (accessed 30 November 2021).

  4. Patridge, E. V. et al. Drug Discov. Today 20, 1182–1187 (2015).

    Article  Google Scholar 

  5. Sampat, B. N. et al. Health Aff. 30, 332–339 (2011).

    Article  Google Scholar 

  6. KEI. (accessed 30 November 2021).

  7. Schlander, M. et al. Ann. Oncol. 31, S966 (2020).

    Article  Google Scholar 

  8. Gilead Sciences. (2021).

  9. FDA. (2019).

  10. Stern, A. D. et al. Health Aff. 40, 989–999 (2021).

    Article  Google Scholar 

  11. Bennette, C. S. et al. Health Aff. 35, 805–812 (2016).

    Article  Google Scholar 

  12. FiercePharma. (2017).

  13. Caffarra, C. et al. (2020).

  14. Love, J. Knowledge Ecology International (2018).

  15. Ledley, F. D. et al. JAMA 323, 834 (2020).

    Article  Google Scholar 

  16. Anderson, R. BBC News (2014).

  17. Statista. (2022).

  18. Liu, M., Feldman, W.B., Avorn, J. & Kesselheim. Health Affairs Forefront (2020).

  19. Novartis Inc. (2021).

  20. Novartis Inc. (2019).

  21. Gilead Sciences. (2019).

  22. AdisInsight. (accessed 30 November 2021).

Download references


This study was funded by the Swiss National Science Foundation (SNSF).

Author information

Authors and Affiliations



Both authors conceptualized the comment. M.N. wrote the first draft. K.N.V. revised and finalized the draft.

Corresponding authors

Correspondence to Melissa Newham or Kerstin N. Vokinger.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Newham, M., Vokinger, K.N. Adverse effects of acquisitions in the pharmaceutical industry. Nat Med 28, 1342–1344 (2022).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing